EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms

Khrystyna Ryabenko iD, Valérie Schini-Kerth iD, Patrick Ohlmann iD, Elena Galli

Biomolecules · 15.06.2026 · 16 (6) · 873

DOI: 10.3390/biom16060873 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 15.06.2026. Verfasst von Khrystyna Ryabenko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Cardiomyopathy, Hypertrophic, Sodium-Glucose Transporter 2. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disorder and a major cause of heart failure (HF) and sudden cardiac death. Although sarcomeric gene mutations initiate the disease, increasing evidence identifies oxidative stress, mitochondrial dysfunction, and maladaptive nutrient signaling as key drivers of disease progression. Enhanced reactive oxygen species (ROS) production in HCM promotes energetic impairment, calcium mishandling, fibrosis, and the activation of pro-hypertrophic pathways, while disrupting protein quality control and endothelial function. Despite recent therapeutic advances, effective disease-modifying strategies targeting these molecular mechanisms remain limited. Sodium–glucose cotransporter 2 inhibitors (SGLT2i), originally developed for type 2 diabetes, have demonstrated robust cardioprotective effects in HF independent of glycemic control. Beyond their renal actions, SGLT2i modulate myocardial metabolism, reduce oxidative stress, improve mitochondrial function, restore sodium and calcium homeostasis, and attenuate inflammation and maladaptive mTOR activation. Emerging preclinical and translational data suggest that these pleiotropic mechanisms may counteract key pathophysiological processes underlying HCM. This review summarizes the molecular interplay between oxidative stress and hypertrophic remodeling in HCM and explores the rationale for SGLT2 inhibition as a potential disease-modifying therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsCardiomyopathy, HypertrophicSodium-Glucose Transporter 2HumansOxidative StressAnimalsReactive Oxygen Species

Stichwörter der Autor:innen

gliflozineshypertrophic cardiomyopathyinflammationreactive oxygen speciessodium–glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2Reactive Oxygen SpeciesSLC5A2 protein, human

Autor:innen und Institutionen

  • Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
  • UR 3074-Translational CardioVascular Medicine, Faculty of Pharmacy, University of Strasbourg, 67000 Strasbourg, France.
  • Division of Cardiovascular Medicine, Nouvel Hospital Civil, Strasbourg University Hospital, 67000 Strasbourg, France.
  • UMR 7357-ICube, CNRS-University of Strabourg, 67084 Strasbourg, France.

ORCID-Profile: Khrystyna Ryabenko, Valérie Schini-Kerth, Patrick Ohlmann

Zitieren

APA

Ryabenko, K., Schini-Kerth, V., Ohlmann, P., & Galli, E. (2026). SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms. Biomolecules, 16(6), 873. https://doi.org/10.3390/biom16060873

Vancouver

Ryabenko K, Schini-Kerth V, Ohlmann P, Galli E. SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms. Biomolecules. 2026;16(6):873. doi:10.3390/biom16060873

BibTeX
@article{Ryabenko2026,
  author = {Ryabenko, Khrystyna and Schini-Kerth, Valérie and Ohlmann, Patrick and Galli, Elena},
  title = {SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {873},
  doi = {10.3390/biom16060873}
}
Kostenlos starten →